Netherlands Research Council Signs Database Subscription Agreement with Celera Genomics
Agreement Allows Publicly Funded Researchers to Access Celera’s Genomic Databases, Tools
Rockville, MD - July 03, 2001
Celera Genomics (NYSE: CRA), an Applera Corporation business, has signed an agreement with the Netherlands Organization for Scientific Research (NWO), that provides a multi-year subscription to Celera’s genomic databases and bioinformatics expertise. Through this agreement, the NWO can provide subscriptions to its publicly funded research institutions. Financial terms of the agreement were not disclosed.
“We are pleased that the scientific community in the Netherlands recognizes the need for accurate genomic data and the tools and software to support their research projects, and through this agreement, has turned to Celera to provide this information” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “We look forward to working with the Dutch research community and aiding them in their quest toward a better understanding of human biology and disease.”
“In the interest of the Dutch academic research in the Life Sciences, the Netherlands Organization of Scientific Research has decided to facilitate access for its academic research community to all relevant genomic data,” said Prof. Dr. Eduard C. Klasen, Director of the Netherlands Organization for Scientific Research NWO. “We expect that the contract with Celera will further enhance the effectiveness of the recent and forthcoming Dutch funding programs in Genomics and Bioinformatics.”
The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.
The Netherlands Organization for Scientific Research NWO is the central Dutch organisation in the field of fundamental and strategic scientific research. NWO encompasses all fields of scholarship. Consequently, NWO plays a key role in the development of science, technology and culture in The Netherlands. NWO acts as the national research council in the Netherlands and is an independent organisation established by Act of Parliament in 1988. It succeeded the Netherlands Organisation for the Advancement of Pure Research (ZWO) established in 1950.
NWO’s budget in 2001 totals about 840 million guilders (approximately 380 million Euro). NWO holds approximately a five- percent share in the total annual investment by government and industry in scientific research and development. Despite this comparatively small share, NWO is the largest national sponsor of fundamental scientific research at the thirteen Dutch universities. NWO employs over 4500 people, of whom 60 percent are associated with Dutch universities. About 35 percent are employed by other academic research institutes and NWO institutes. In the Netherlands, the name “NWO” is almost automatically equated with “quality”, in the sense that NWO’s acceptance of a research proposal is regarded as a guarantee for good quality. However, the organisation feels a constant obligation to strive to meet the highest international standards in the quality of its research. NWO’s prime concern is to establish and maintain high scientific standards. The Act of 1988 states that “the organisation is to be responsible for promoting the quality of academic research, initiating and encouraging new developments, notably by allocating funds. Over two-thirds of NWO expenditure benefits academic research in universities, which means that NWO is responsible for about 17 percent of the national academic research capacity. In addition, almost 30 percent of the budget is spent on NWO’s fifteen national research institutes.
Applera Corporation comprises two operating groups. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation diagnostic and therapeutic discovery company. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for subscribers and for its own internal product development. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in forward-looking statements within this press release. The risks and uncertainties include but are not limited to: (1) dependence on the final assembly and annotation of the human genome; (2) unproven use of genomics information to develop products; (3) dependence on computer hardware, software, and internet applications; (4) potential adverse effect on the Celera Genomics group’s intellectual property protection and the value of its products and services due to public disclosure of genomics sequence data; (5) government regulation of Celera’s products and services; and (6) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.